Ownership Submission
FORM 5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Form 3 Holdings Reported
Form 4 Transactions Reported
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0362
Expires: January 31, 2005
Estimated average burden hours per response... 1.0

1. Name and Address of Reporting Person *
Kammer Robert J
 2. Issuer Name and Ticker or Trading Symbol
Imprimis Pharmaceuticals, Inc. [IMMY] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last)
(First)
(Middle)

C/O IMPRIMIS PHARMACEUTICALS, INC., 437 S. HIGHWAY 101, SUITE 209		 3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
12/31/2012
(Street)


SOLANA BEACH, CA 92075		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Reporting
(check applicable line)

_X_ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Amount (A) or (D) Price
Common Stock 02/28/2012   C4(1) 1,454,962 A $ 0 0 (2) I DermaStar International, LLC (2)
Common Stock 04/30/2012   J4(5) 193,047 A $ 762,534 0 (2) I DermaStar International, LLC (2)
Common Stock             891,491 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 2270 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
(A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Convertible Debenture $ 0.6668 01/01/2012   P4 856,087   02/28/2012 04/05/2012 Common Stock
1,454,962
$ 50,000 0
I
DermaStar International, LLC (2)
Convertible Debenture $ 0.6668 02/28/2012   C4   856,087 02/28/2012 04/05/2012 Common Stock
1,454,962
$ 0 0
I
DermaStar International, LLC (2)
Option (Right to Buy) $ 4.5 04/01/2012   A4 60,000     (3) 03/31/2017 Common Stock
60,000
$ 0 60,000
D
 
Option (Right to Buy) $ 4.5 04/01/2012   A4 25,000     (4) 03/31/2017 Common Stock
25,000
$ 0 25,000
D
 
Warrants $ 5.925 04/30/2012   P4 48,262   04/30/2012 04/29/2015 Common Stock
48,262
$ 0 0
I
DermaStar International, LLC (2)
Warrants $ 5.925 07/12/2012   J4 (6) 2,413   04/30/2012 04/20/2015 Common Stock
2,413
$ 0 2,413
D
 

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kammer Robert J
C/O IMPRIMIS PHARMACEUTICALS, INC.
437 S. HIGHWAY 101, SUITE 209
SOLANA BEACH, CA 92075		   X   X   Chief Executive Officer  

Signatures

/s/ Robert Kammer 03/15/2013
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents the shares of common stock acquired by DermaStar International, LLC ("DermaStar") upon automatic conversion of a convertible debenture issued by the Issuer on April 5, 2010 and acquired by DermaStar in a private transaction on January 1, 2012.
(2) Reporting person was a managing member of DermaStar at the time of the reported transaction and may be deemed to have voting and dispositive power over such shares. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. As previously reported on a Form 4 filed on July 20, 2012, on July 12, 2012 DermaStar distributed to its members all securities of the Issuer held by it and was subsequently dissolved.
(3) The stock options were granted under the Issuer's 2007 Stock Incentive and Awards Plan and vest over a 2 year period, with 15,000 options vesting immediately upon issuance, and an additional 1,875 options vesting monthly for the next twenty four months thereafter.
(4) The stock options were granted under the Issuer's 2007 Stock Incentive and Awards Plan and vest over a 1 year period, with the initial 6,250 options vesting on June 30, 2012, the next 6,250 options vesting on September 30, 2012, the next 6,250 options vesting on December 31, 2012 and the final 6,250 options vesting on March 31, 2013.
(5) Represents shares received upon the exchange of amounts owing under an outstanding Line of Credit into common stock of the Issuer.
(6) Represents warrants distributed by DermaStar to its members on July 12, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.